Title:
リンパ腫を処置するためのＥＺＨ２阻害剤
Document Type and Number:
Japanese Patent JP6890097
Kind Code:
B2
Abstract:
The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
Inventors:
Hike keel hack
Sara K. Natson
Elle Daniel Johnston
Sara K. Natson
Elle Daniel Johnston
Application Number:
JP2017564058A
Publication Date:
June 18, 2021
Filing Date:
June 10, 2016
Export Citation:
Assignee:
EPIZIM, INCORPORATED
International Classes:
A61K31/5377; A61K31/437; A61K31/4545; A61K31/501; A61K31/517; A61K31/519; A61K31/5517; A61P35/00; A61P43/00
Domestic Patent References:
| JP2014534178A | ||||
| JP2013543114A | ||||
| JP2017518334A |
Foreign References:
| WO2014062732A1 | ||||
| WO2014062720A1 | ||||
| WO2013155464A1 |
Other References:
PLoS ONE (2014), 9(12): e111840
Phase 1 Dose Escalation Data for Epizyme EZH2 Inhibitor EPZ-6438 (E7438) Shows Single Agent Activity in B-Cell Non-Hodgkin Lymphomas and Malignant Rhabdoid Tumor [online] Epizyme, Inc. 2014-11-19, URL [検索日:2020-5-18]
Phase 1 Dose Escalation Data for Epizyme EZH2 Inhibitor EPZ-6438 (E7438) Shows Single Agent Activity in B-Cell Non-Hodgkin Lymphomas and Malignant Rhabdoid Tumor [online] Epizyme, Inc. 2014-11-19, URL
Attorney, Agent or Firm:
Murai Koji
Horikawa Kaori
Horikawa Kaori